Lazertinib trials for Carcinoma, Non-Small-Cell Lung

All Lazertinib trials · All Carcinoma, Non-Small-Cell Lung trials

Phase breakdown

Recruiting trials studying Lazertinib for Carcinoma, Non-Small-Cell Lung

• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 203 locations
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
  NCT07586202 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations

Common questions

How many trials study Lazertinib for Carcinoma, Non-Small-Cell Lung?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.